COVID-19 studies:
C19 studies:
C19:
Ivermectin
IVM
Vitamin D
V.D
PX
PX
FLV
FLV
PVP-I
PI
BU
BU
BH
BH
BL
BL
CI
CI
HC
Q
HC
Q
NZ
NZ
CO
CO
More..
COVID-19 studies:
C19 studies:
C19:
Ivermectin
IVM
Vitamin D
V.D
PX
PX
FLV
FLV
PVP-I
PI
BU
BU
BH
BH
BL
BL
CI
CI
HC
Q
HC
Q
NZ
NZ
CO
CO
More..
Home
Share
Tweet
PDF
Meta Analysis
Meta
Global Adoption
Adoption
Submit Feedback
Feedback
Download Image
Share
Tweet
Download Image
Share
Tweet
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gautret
66%
0.34 [0.17-0.68]
2.4g
viral+
6/20
14/16
Improvement, RR [CI]
Dose (4d)
Treatment
Control
Huang (RCT)
92%
0.08 [0.01-1.32]
4.0g (c)
no recov.
0/10
6/12
Esper
64%
0.36 [0.15-0.87]
2.0g
hosp.
8/412
12/224
Ashraf
68%
0.32 [0.10-1.10]
1.6g
death
10/77
2/5
Huang (ES)
59%
0.41 [0.26-0.66]
2.0g (c)
viral time
32/32
37/37
Guérin
61%
0.39 [0.02-9.06]
2.4g
death
0/20
1/34
Chen (RCT)
72%
0.28 [0.10-0.82]
1.6g
viral time
18/18
12/12
Derwand
79%
0.21 [0.03-1.47]
1.6g
death
1/141
13/377
Mitjà (RCT)
16%
0.84 [0.35-2.03]
2.0g
hosp.
8/136
11/157
Skipper (RCT)
37%
0.63 [0.21-1.91]
3.2g
hosp./death
5/231
8/234
Hong
65%
0.35 [0.13-0.72]
n/a
viral+
42/42
48/48
Bernabeu-Wittel
59%
0.41 [0.36-0.95]
2.0g
death
189 (n)
83 (n)
Yu (ES)
85%
0.15 [0.02-1.05]
1.6g
death
1/73
238/2,604
Ly
56%
0.44 [0.26-0.75]
2.4g
death
18/116
29/110
Ip
55%
0.45 [0.11-1.85]
n/a
death
2/97
44/970
Heras
96%
0.04 [0.02-0.09]
n/a
death
8/70
16/30
Kirenga
26%
0.74 [0.37-1.48]
n/a
recov. time
29/29
27/27
Sulaiman
64%
0.36 [0.17-0.80]
2.0g
death
7/1,817
54/3,724
Guisado-Vasco (ES)
67%
0.33 [0.05-1.55]
n/a
death
2/65
139/542
Szente Fonseca
64%
0.36 [0.20-0.67]
2.0g
hosp.
25/175
89/542
Cadegiani
81%
0.19 [0.01-3.88]
1.6g
death
0/159
2/137
Simova
94%
0.06 [0.00-1.13]
2.4g
hosp.
0/33
2/5
Omrani (RCT)
12%
0.88 [0.26-2.94]
2.4g
hosp.
7/304
4/152
Agusti
68%
0.32 [0.06-1.67]
2.0g
progression
2/87
4/55
Su
85%
0.15 [0.04-0.57]
1.6g
progression
261 (n)
355 (n)
Amaravadi (RCT)
60%
0.40 [0.13-1.28]
3.2g
no recov.
3/15
6/12
Roy
2%
0.98 [0.45-2.20]
n/a
recov. time
14 (n)
15 (n)
Mokhtari
70%
0.30 [0.20-0.45]
2.0g
death
27/7,295
287/21,464
Million
83%
0.17 [0.06-0.48]
2.4g
death
5/8,315
11/2,114
Sobngwi (RCT)
52%
0.48 [0.09-2.58]
1.6g
no recov.
2/95
4/92
Early treatment
65%
0.35 [0.24-0.49]
268/20,348
1,120/34,189
65% improvement
All 30 hydroxychloroquine COVID-19 early treatment studies
hcqmeta.com 8/4/21
Tau​
2
​
= 0.61; I​
2
​
= 87.0%; Z = 5.92 (p < 0.0001)
Effect extraction pre-specified, see appendix
Lower Risk
Increased Risk
Download Image
Share
Tweet
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
All studies
Early treatment
Effects reported
in all COVID-19
hydroxychloroquine studies
min, Q1, median, Q3, max
Lower Risk
Increased Risk
hcqmeta.com 8/4/21
Download Image
